Discovery of Novel Molecular Targets for Neurodegenerative Diseases
LAS VEGAS, NV–(Marketwired – August 01, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), cited a recent study conducted by researchers at the University of Louisville School of Medicine suggesting a scientific basis for the potential of cannabidiol (CBD) to have therapeutic value in two neurodegenerative diseases, Alzheimer’s and Parkinson’s.
The investigative team at the University of Louisville studied endogenous cannabinoids (“endocannabinoids”) as well as botanical cannabinoids (“phytocannabinoids”) like CBD and concluded that CBD was a significant ligand that was the most potent of the cannabinoids for two molecular receptors, GPR3 and GPR6, which are implicated in the pathogenesis of Alzheimer’s and Parkinson’s disease, respectively.
Understanding the molecular pathways involved in neurodegenerative diseases and identifying potential ligands (drugs that bind to the receptors) that can be administered to humans is critical for drug development. Prior to this research (“GPR3 and GPR6, novel molecular targets for cannabidiol”) published in the May 29, 2017 Journal of Biochemical and Biophysical Research Communications, it was unknown that CBD could bind to these receptors and act as an inverse agonist. The results of this study now suggest that GPR3 and GPR6 may mediate therapeutic effects of CBD administration, which could be important for treatment of Alzheimer’s and Parkinson’s diseases.
CV Sciences focuses on the development and commercialization of proprietary prescription drugs utilizing synthetic CBD as the active pharmaceutical ingredient. Its initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco and tobacco addiction.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.